Scientists from Barcelona are conducting a study to see if the loss of smell may be a preclinical marker to predict the possible occurrence of Parkinson’s disease.
The neurologist of the Unit of Parkinson and Movement Disorders from Hospital Clínic of Barcelona, Eduard Tolosa, has participated in a conference organized by the Catalan Association for Parkinson (ACAP) which has been reviewed investigations to try curing this disease and the role in his patients.
The vast majority of current research focus their efforts on the genetic Parkinson but in addition to these studies, the Barcelona hospital has open other main research on this disease.
The study of olfaction want to relate the loss of smell as a preclinical marker as it appears before the development of the disease and affects 90% of those affected by Parkinson’s.
The neurologist also encouraged to volunteer in studies being held at Hospital Clinic, because Parkinson’s does not start when the first mobility problems appear, it begins many years before.
Depression, sleep disorders or loss of smell may be some of the indicators in this initial phase or Pre-Clinical disease.
These parameters should be assessed taking into consideration the most important risk factors: age (Parkinson’s is more prevalent the older is the person) or sex, affecting nearly doubled in males than in females.
According to the Catalan Association for Parkinson’s, there are also factors to take into account: the consumption of nicotine (nicotine could slow the progression of the disease) and consumption of coffee (caffeine helps reduce the risk of Parkinson’s) and the research tries to define the range of optimal tolerance.